Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

about

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.

P2860

Q38711101-CFF3512C-FA35-4EA9-9CB3-AED04D5EB378 Q55312290-3D6FA6DE-C001-4EE0-8FBD-45CA4F4BA41A

P2860

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

Item

http://www.wikidata.org/entity/Q38965866

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Peptide receptor chemoradionuc ...... cinoma: from bench to bedside.

@en

type

Item

label

Peptide receptor chemoradionuc ...... cinoma: from bench to bedside.

@en

prefLabel

Peptide receptor chemoradionuc ...... cinoma: from bench to bedside.

@en

P1476

Peptide receptor chemoradionuc ...... cinoma: from bench to bedside.

@en

P2093

Aparna Rao

http://www.w3.org/2001/XMLSchema#string

D Neil Watkins

http://www.w3.org/2001/XMLSchema#string

Jeremy Lewin

http://www.w3.org/2001/XMLSchema#string

Kelly Waldeck

http://www.w3.org/2001/XMLSchema#string

Linda Mileshkin

http://www.w3.org/2001/XMLSchema#string

Peter Eu

http://www.w3.org/2001/XMLSchema#string

Tim Akhurst

http://www.w3.org/2001/XMLSchema#string

P2860

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice.

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer

A crucial requirement for Hedgehog signaling in small cell lung cancer

P2888

s00259-014-2888-2

P304

25-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-014-2888-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carleen Cullinane

Rodney J. Hicks

P577

2014-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264795613

http://www.w3.org/2001/XMLSchema#string

P698

25125202

http://www.w3.org/2001/XMLSchema#string

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

about

P2860

P2860

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698